Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma
| Autor: | Hidetoshi Taguchi, Kazuyoshi Nakamura, Satoshi Chiba, Hideyuki Takano, Akihiro Imamura, Hiroyuki Funatsu, Hidehito Arimitsu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Carcinoma Hepatocellular Hepatocellular carcinoma medicine.medical_treatment Acrylic Resins Antineoplastic Agents Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Chemoembolization Therapeutic Adverse effect Aged Retrospective Studies Cause of death Aged 80 and over Cisplatin TACE business.industry Liver Neoplasms Fine-powder cisplatin Middle Aged medicine.disease Survival Rate Radiation therapy Treatment Outcome 030220 oncology & carcinogenesis Bland Embolization Toxicity Trisacryl gelatin microsphere Gelatin Original Article Female Liver function Powders business medicine.drug |
| Zdroj: | Japanese Journal of Radiology |
| ISSN: | 1867-108X 1867-1071 |
| DOI: | 10.1007/s11604-020-01078-1 |
| Popis: | Purpose To evaluate the safety and effectiveness of whole-liver transcatheter arterial chemoinfusion and bland embolization (TACBE) with fine-powder cisplatin and trisacryl gelatin microspheres for the treating unresectable multinodular hepatocellular carcinoma (HCC). Materials and methods The medical records of all patients who underwent TACBE sessions were retrospectively reviewed. 15 patients (11 men, 4 women; mean age, 72.5 years) and 22 procedures (BCLC B;17 C;5) were included in the analysis. The cisplatin resulting solution and microspheres were infused through a microcatheter placed nonselectively. Overall survival (OS) was defined as the time from commencement of initial TACBE until any cause of death. Toxicity was assessed by the CTCAE version 5.0, and the tumor response was evaluated by the mRECIST. Liver function was assessed by the albumin–bilirubin (ALBI) score. Results The 1-year OS rate was 64.6% (95% CI 0.438–0.955). Severe adverse effects were not observed except for grade 3 increase in the ALT, ALT, vasovagal episode. The objective response and disease control rare were 54.5% and 68.2%, respectively. The ALBI scores from pre-treatment to the follow-up ranged from − 2.39 to − 2.26 (p = 0.38). Conclusion Whole-liver TABCE with fine-powder cisplatin and trisacryl gelatin microspheres was well tolerated and effective in patients with multinodular HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink